

Available from Guardant Health: **A full suite of IHC testing.**

Refer to the list of clinically relevant IHC biomarkers by tumor type below,
and select them directly on your order form.

Lung

**c-MET,
HER2, PD-L1**

Breast

**ER/PR, HER2,
Ki-67, MMR*, PD-L1**

Colorectal

MMR, HER2

Gastric

**CLDN18, HER2
MMR, PD-L1**

Ovarian

**FOLR1,
HER2, MMR**

>20% improved PD-L1 detection with AI-powered scoring.^{†1}

IHC, Immunohistochemistry.

* Guidelines state MMR is useful in certain circumstances for breast cancer patients who have no satisfactory alternative treatment options.

† Compared to manual pathologist interpretation in the most challenging cases of NSCLC.

Reference: 1. Choi S, et al. Eur J Cancer. 2022;170:17-26. doi:10.1016/j.ejca.2022.04.011

Get IHC results as an add-on to Guardant360 Tissue.[‡]

IHC sample requirements:

c-MET, FOLR1, HER2, Ki-67, PD-L1




1 unstained slide each

CLDN18, ER/PR[§]



2 unstained slides each

MMR



4 unstained slides

Convenient ordering

Easily add IHC tests to a Guardant360 Tissue order via the paper order form, online portal, or EMR.[‡]

EMR, electronic medical record.

[‡] IHC results are issued as a separate clinical report.

[§] ER/PR are ordered together and require one unstained slide each for a total of 2 unstained slides.

Important note: Guardant360 Tissue was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been reviewed or approved by the US FDA.

© 2026 Guardant Health Inc. All rights reserved. ONC-US-00169 V4

